Talazoparib Is Active in gBRcA1/2 Mutation-Positive Early HER2-Negative Breast Cancer
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
Black patients were more likely than White patients to have distant metastases.
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.